Article

Victoza® LEAD Clinical Trial Program

Victoza® studies included nearly 4000 patients in the Liraglutide Effect and Action in Diabetes (LEAD) trials. Click here for more information.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit: kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Related Content
Pregnant woman eating fresh vegetable salad, sitting on a sofa, healthy pregnancy concept - Image credit: Anna | stock.adobe.com
July 10th 2025

Maternal Pro-Inflammatory Diet During Pregnancy Linked to Increased Type 1 Diabetes Risk in Offspring

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike
July 10th 2025

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Gustavo Alva, MD Luke Halpern, Assistant Editor
Abstract representation of cholesterol levels with colorful particles floating. This illustrates complexity of blood components and cholesterol
July 10th 2025

With Proper Adherence to Cholesterol-Lowering Drugs, Thousands of Cardiovascular Events Could Be Avoided

Luke Halpern, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Hyperlipidemia or arteriosclerosis. Blocked artery concept and human blood vessel as a disease with cholesterol fat buildup clogging. Clogged arteries, Cholesterol plaque in the artery. 3D
July 9th 2025

Reassessing the Safety and Efficacy of Very Low LDL Cholesterol

Maria DelPizzo, Senior Clinical Pharmacist Orgesa Cepo, Senior Clinical Pharmacist
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025

Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies

Jennifer D. Goldman, PharmD, CDE, BC-ADM, FCCP Alana Hippensteele, Lead Editor